BIOMAT Database Logo BIOMAT Database Logo

Antibody dependent cellular cytotoxicity and complement mediated cytotoxicity on leukemic cells mediated by anti K562 monoclonal antibodies. 1990

R J Tatake, and H S Maniar, and S V Chiplunkar, and R Somasundaram, and M K Amin, and T Saikia, and S G Gangal
Immunology Division, Cancer Research Institute, Bombay, India.

Three anti K562 monoclonal antibodies (MAb) 4.3, 4.6 and 4.8 reacting predominantly with cells of myeloid lineage, were tested for antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). MAb 4.6 (IgG3k) effectively mediated ADCC against K562 cells and fresh leukemic targets with effectors from healthy donors. However, for ADCC on chronic myeloid leukemia (CML) targets, effectors from CML patients in remission needed modulation with IL-2. All MAb showed significant CDC against peripheral blood (PB) and bone marrow (BM) cells obtained from CML patients in chronic phase, and untreated acute myeloid leukemia (AML) patients. MAb displayed no CDC against PB and BM cells from CML patients in remission and BM cells of Hodgkin's Disease (HD) patients with normal BM cellularity. In clonogenic assay, colony forming units (CFU) in the BM aspirate obtained from CML patients in chronic phase were significantly reduced by treatment with MAb and complement.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D004915 Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood. Di Guglielmo's Disease,Erythremic Myelosis,Erythroblastic Leukemia, Acute,Erythroleukemia,Leukemia, Myeloid, Acute, M6,Myeloid Leukemia, Acute, M6,Di Guglielmo Disease,Acute Erythroblastic Leukemia,Acute Erythroblastic Leukemias,Di Guglielmos Disease,Disease, Di Guglielmo,Disease, Di Guglielmo's,Erythremic Myeloses,Erythroblastic Leukemias, Acute,Erythroleukemias,Leukemia, Acute Erythroblastic,Leukemias, Acute Erythroblastic,Myeloses, Erythremic,Myelosis, Erythremic
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

R J Tatake, and H S Maniar, and S V Chiplunkar, and R Somasundaram, and M K Amin, and T Saikia, and S G Gangal
Antibody dependent cellular cytotoxicity mediated by HLA-class II specific monoclonal antibodies.
September 1986, Tissue antigens,
R J Tatake, and H S Maniar, and S V Chiplunkar, and R Somasundaram, and M K Amin, and T Saikia, and S G Gangal
Anti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells.
December 2012, Medical oncology (Northwood, London, England),
R J Tatake, and H S Maniar, and S V Chiplunkar, and R Somasundaram, and M K Amin, and T Saikia, and S G Gangal
Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity.
December 2006, Cancer biotherapy & radiopharmaceuticals,
R J Tatake, and H S Maniar, and S V Chiplunkar, and R Somasundaram, and M K Amin, and T Saikia, and S G Gangal
Anti-Trichomonas vaginalis monoclonal antibodies inducing complement-dependent cytotoxicity.
January 1988, Immunology,
R J Tatake, and H S Maniar, and S V Chiplunkar, and R Somasundaram, and M K Amin, and T Saikia, and S G Gangal
Antibody-dependent-cellular-cytotoxicity against cultured human breast cancer cells mediated by human effector cells using monoclonal and polyclonal antibodies.
December 1983, British journal of cancer,
R J Tatake, and H S Maniar, and S V Chiplunkar, and R Somasundaram, and M K Amin, and T Saikia, and S G Gangal
Complement-dependent cytotoxicity of anti-human osteogenic sarcoma monoclonal antibodies.
October 1982, British journal of cancer,
R J Tatake, and H S Maniar, and S V Chiplunkar, and R Somasundaram, and M K Amin, and T Saikia, and S G Gangal
Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
October 2002, Cancer immunity,
R J Tatake, and H S Maniar, and S V Chiplunkar, and R Somasundaram, and M K Amin, and T Saikia, and S G Gangal
Variance in resistance to natural and antibody-dependent cellular cytotoxicity and to complement-mediated lysis among K562 lines.
August 1983, International journal of cancer,
R J Tatake, and H S Maniar, and S V Chiplunkar, and R Somasundaram, and M K Amin, and T Saikia, and S G Gangal
Complement-dependent cytotoxicity of monoclonal antibodies against islet cells.
January 1985, Biomedica biochimica acta,
R J Tatake, and H S Maniar, and S V Chiplunkar, and R Somasundaram, and M K Amin, and T Saikia, and S G Gangal
An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab.
March 2012, Molecular immunology,
Copied contents to your clipboard!